An ongoing study is attempting to build on what researchers have learned in recent years regarding neoadjuvant approaches to immunotherapy for high-risk melanoma.
Archive | Health Professionals
Garutti Examines Advantages of Neoadjuvant Approaches in Melanoma
The use of adjuvant therapies in melanoma could offer superior efficacy compared to what is currently provided by adjuvant therapies alone, with some preclinical data pointing to increased clinical benefit within this patient population, according to Mattia Garutti, MD.
Posted in Melanoma News, Health Professionals, Of Interest
Melanoma ‘calculator’ for skin cancer risk
Australians will now be able to determine their likelihood of developing melanoma in under a minute with a new lifetime risk ‘calculator’.
Posted in Melanoma News, Health Professionals, Of Interest
Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma
Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
